Project Grant R41AG085737
Award Date
9/25/24
Completion Date
8/31/25
Dollars Obligated
$1M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Similar Awards
This federal Project Grant award of $949,062 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel nanomaterial-based drug delivery system to improve treatment of Alzheimer's disease (AD) and other dementias. The primary objective is to demonstrate the in vitro and in vivo effectiveness of a natural peptide-based nanostructure called SMC-101 nanotubes (NTs) for transcytosis across the blood-brain barrier and safe delivery of CNS drugs. Key research...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
This Project Grant award for $506,451 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) aims to develop an effective targeted delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, including Alzheimer's disease. The project leverages the awardee's 3P Biotechnologies, Inc.'s expertise in exosome engineering, drug delivery, and siRNA therapeutics. The key products or services to be delivered under this award...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
This Project Grant award, funded by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866), supports research to evaluate the efficacy of a novel therapeutic approach targeting neuroinflammation for protecting against brain aging and Alzheimer's disease-related pathology. The $679,424 award will enable comprehensive preclinical studies to test the ability of NF-κB/NLRP3-targeted nanoligomers to reduce neuroinflammation and protect cognitive function in...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,998.00 to Encue Inc., a small disadvantaged business located in Evanston, IL, to develop novel small molecule modulators of synaptic plasticity for the treatment of Alzheimer's disease (AD)-induced cognitive decline. The project aims to further develop the lead molecule JB2 as a therapeutic to reverse or delay the onset of cognitive dysfunction in AD by restoring normal expression...
This Project Grant award from the National Institutes of Health's National Institute on Aging (CFDA 93.866 - Aging Research) provides $613,571 to the University of Chicago to develop a novel therapeutic approach for treating Alzheimer's disease. The funding will support the development of lipid nanoparticles containing mRNA encoding an anti-amyloid-beta chimeric antigen receptor (CAR) and interleukin-10 (IL-10) to induce an anti-inflammatory microglial response in the brain. The goal is to...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...
This federal Project Grant award of $1,055,595 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to better understand how advancing age contributes to the occurrence and progression of Alzheimer's disease (AD). The key objectives are to: 1) determine how increasing endosome formation, the vehicles for endosome trafficking, can decrease tau protein accumulation in neurons, a hallmark of AD pathology; and 2) define how increasing endosome formation influences cognition and...